The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

Jul. 24, 2017
Applicant:

Ascend Biopharmaceuticals Ltd, South Melbourne, AU;

Inventor:

Clement Leong, South Melbourne, AU;

Assignee:

Ascend Biopharmaceuticals Ltd, South Melbourne, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/706 (2006.01); A61K 31/235 (2006.01); A61K 31/4439 (2006.01); A61K 31/505 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 31/739 (2006.01); A61K 35/761 (2015.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01); C07K 14/57 (2006.01); A61K 38/16 (2006.01); A61K 31/22 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/706 (2013.01); A61K 9/0014 (2013.01); A61K 31/22 (2013.01); A61K 31/235 (2013.01); A61K 31/4439 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 31/739 (2013.01); A61K 35/761 (2013.01); A61K 38/16 (2013.01); A61K 38/19 (2013.01); A61K 38/191 (2013.01); A61K 38/195 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 38/21 (2013.01); A61K 38/217 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/57 (2013.01); C12N 15/86 (2013.01); C12N 2710/10033 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10333 (2013.01); C12N 2710/10343 (2013.01); C12N 2770/24032 (2013.01); C12N 2770/24043 (2013.01);
Abstract

The present invention relates to methods of treating cancer in a human subject in need thereof. In particular, the present invention relates to treating a cancer by administering a recombinant virus which expresses one or more biotherapeutic agents in a subject, and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent. The invention further relates to method for treating cancer by administering a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent and a caspase inhibitor, and, optionally, also administering a recombinant virus expressing one or more biotherapeutic agents in the subject. The invention also relates to a method for treating cancer by administering purified interferon gamma to a subject and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent. Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions containing: a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent and a recombinant virus; a nucleotide analogue or nucleotide analogue precursor chemotherapeutic agent and a caspase inhibitor; or a purified interferon gamma and a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent.


Find Patent Forward Citations

Loading…